Skip to content
Study details
Enrolling now

A Study of SPY072 in Rheumatic Disease

Spyre Therapeutics, Inc.
NCT IDNCT07148414ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

285

Study length

about 2.6 years

Ages

18+

Locations

13 sites in AZ, CA, FL +2

What this study is about

This trial is testing a treatment called SPY072 compared to a placebo in adults with rheumatic diseases. The goal is to see if SPY072 is effective and safe for this condition.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Placebo
  • 2.Take SPY002-072

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Axial Spondyloarthritis: Change from baseline in Ankylosing Spondylitis Disease Activity Score (ADAS), Rheumatoid Arthritis: Change from baseline in Disease Activity Score in 28 joints (c-reactive protein) (DAS-CRP)

Secondary: Psoriatic Arthritis: Change from baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA)

Body systems

Dermatology, Immune, Musculoskeletal